RecruitingMetastatic Colorectal Cancer
Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study is being done to see if combining liposomal irinotecan with TAS102 and bevacizumab confers clinical benefit for patients with treatment refractory metastatic colorectal cancer.
Sponsor: University of Wisconsin, Madison
You may qualify if…
- ✓ Patients must be ≥ 18 years of age
- ✓ Eastern Cooperative Oncology Group (ECOG) performance must be 0 or 1.
- ✓ Patients must have a histologically or cytologically confirmed diagnosis of colorectal adenocarcinoma and be metastatic or unresectable.
- ✓ The cancer must be mismatch repair proficient.
- ✓ Patients must have had prior treatment with 5-fluorouracil, oxaliplatin, irinotecan containing regimens. If RAS wild-type must have received prior anti-EGFR therapy with either cetuximab or panitumumab. If RAS wild-type and HER2 positive then must have had a prior HER2 targeted therapy.
You may not qualify if…
- ✕ Uncontrolled concurrent medical illness that would not allow for the completion of the planned therapy.
- ✕ Patients whose cancers possess BRAF V600 mutations are excluded.
- ✕ Patients must stop the use of strong inducers/inhibitors of CYP3A4 at least 2 weeks before initiating therapy.
- ✕ Patients must not have mismatch repair deficient or microsatellite instability high cancers.
- ✕ Patients must not have received prior TAS102.
Where it's recruiting
Wisconsin
Madison
Source: ClinicalTrials.gov · NCT05854498 · last updated 2026-04-02